Tuberculosis vaccine - Archivel Farma

Drug Profile

Tuberculosis vaccine - Archivel Farma

Alternative Names: RUTI

Latest Information Update: 21 Feb 2017

Price : $50

At a glance

  • Originator Archivel Farma
  • Class Antituberculars; Recombinant fusion proteins; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 14 Feb 2017 Phase-II clinical trials in Tuberculosis (Prevention) in Spain (SC) (EudraCT2016-004311-12)
  • 23 Mar 2016 University Medical Center Groningen and Archivel Farma plan a phase IIa trial for Tuberculosis (Treatment-resistant) in the Netherlands (NCT02711735)
  • 20 Aug 2015 No recent reports on development identified - Phase-I for Tuberculosis (Prevention) in Spain (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top